bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
Business Wire•07/08/2026•08:00 ET
0
Whiz Insights
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
CyPath Lung test volume increased 216% year over year in Q2 2026
Get started
Create a free account to read the full story.